Anthony Yii Singapore

Clin Asst Prof Anthony Yii is a Senior Consultant with the Department of Respiratory & Critical Care Medicine at Changi General Hospital (CGH). Dr Yii obtained his medical degree from the University of Cambridge and was accredited as a specialist in Respiratory Medicine in 2017. He specialises in the management of respiratory conditions and holds a Master of Public Health from Johns Hopkins University, focusing on Epidemiology and Biostatistics. Dr Yii serves as the clinical lead for value-driven care and quality improvement initiatives for chronic obstructive pulmonary disease (COPD) at both the hospital and healthcare cluster levels. In this role, he leads initiatives to optimise care delivery, enhance patient outcomes, and improve cost-effectiveness in respiratory care. He is also a member of the Pharmacy and Therapeutics committee, and SingHealth Centralised Institutional Review Board (CIRB). Dr Yii’s research primarily focuses on asthma, COPD, and airway diseases, reflecting his dedication to advancing evidence-based approaches to healthcare quality and population health. His contributions to the field have been recognised at platforms such as the SingHealth Publish! Award and the Johns Hopkins Master of Public Health Capstone Award for Outstanding Achievement.
Job Title
Senior Consultant
Faculty / Department / Division
Respiratory and Critical Care Medicine
Institution / Organisation
Changi General Hospital

20 November 2026, Friday

Time Session
11:00
12:00
Aisya Natasya Musa Chairperson Malaysia
Diahn-Warng Perng Chairperson Taiwan
  • Azza Omar Speaker Malaysia
  • Anthony Yii Speaker Singapore
    Acute asthma exacerbations are conventionally treated with a standard course of systemic corticosteroids, regardless of the underlying inflammatory phenotype. However, increasing evidence suggests that exacerbations are biologically heterogeneous, with differences in corticosteroid responsiveness between type 2-high and type 2-low inflammation. Repeated corticosteroid exposure also contributes to substantial long-term morbidity and healthcare costs. This presentation examines the rationale and emerging evidence for biomarker-directed treatment of acute asthma exacerbations. Transcriptomic studies demonstrate differential corticosteroid effects across inflammatory pathways, while clinical studies suggest that physiological responses may vary according to inflammatory phenotype. Findings from a randomized controlled trial evaluating blood eosinophil-guided corticosteroid duration in hospitalized asthma exacerbations will be presented, alongside emerging evidence for biologic therapies during acute exacerbations. Together, these findings support a shift towards more individualized exacerbation management, with the potential to reduce unnecessary corticosteroid exposure while maintaining clinical effectiveness. Larger confirmatory trials are needed before widespread implementation.
  • Peter Gibson Speaker Australia
  • Q&A
Ballroom 1, Lower Ground Floor